Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ejca.2020.06.017 http://scihub22266oqcxt.onion/10.1016/j.ejca.2020.06.017 32619884!7315961!32619884     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32619884&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Eur+J+Cancer 2020 ; 136 (?): 4-6 Nephropedia Template TP {{tp|p=32619884|t=2020. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?|pdf=|usr=}}{{32619884}} gab.com Text Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine JO: Eur J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=32619884 #FOAvip A vaccine against SARS-CoV-2 might represent the most promising approach to halt durably the current COVID-19 pandemic. We believe that anti-CD20 therapy may jeopardise the efficacy of such a vaccine. This is regrettable because patients receiving anti-CD20 therapy (i.e. those with haematologic malignancies or autoimmune disorders) are particularly at risk of severe COVID-19 and, as such, are the most in need of a vaccine. Here, we review the reasons why anti-CD20 therapy may abrogate or diminish the efficacy of a vaccine against SARS-CoV-2 and we draw physicians' attention towards this potential risk so that it can be considered when evaluating the risk/benefit ratio of anti-CD20 therapy during the current pandemic. Twit Text FOAVip Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine ????Eur J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=32619884 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32619884 #FOAvip English Wikipedia <ref>{{Cite pmid|32619884}}</ref> Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? #MMPMID32619884 Houot R; Levy R; Cartron G; Armand P Eur J Cancer 2020[Sep]; 136 (?): 4-6 PMID32619884show ga A vaccine against SARS-CoV-2 might represent the most promising approach to halt durably the current COVID-19 pandemic. We believe that anti-CD20 therapy may jeopardise the efficacy of such a vaccine. This is regrettable because patients receiving anti-CD20 therapy (i.e. those with haematologic malignancies or autoimmune disorders) are particularly at risk of severe COVID-19 and, as such, are the most in need of a vaccine. Here, we review the reasons why anti-CD20 therapy may abrogate or diminish the efficacy of a vaccine against SARS-CoV-2 and we draw physicians' attention towards this potential risk so that it can be considered when evaluating the risk/benefit ratio of anti-CD20 therapy during the current pandemic. |*Antigens, CD20[MESH] |Antibodies, Monoclonal, Humanized/adverse effects[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Vaccines[MESH] |Coronavirus Infections/*prevention & control[MESH] |Drug Interactions[MESH] |Humans[MESH] |Immunologic Factors/*adverse effects[MESH] |Pandemics/*prevention & control[MESH] |Pneumonia, Viral/*prevention & control[MESH] |Rituximab/*adverse effects[MESH] |SARS-CoV-2[MESH] |Treatment Outcome[MESH]Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccin(epmc).pdf DeepDyve Pubget Overpricing